前列腺放疗中均匀与非均匀推量:治疗计划与靶区剂量学比较
本研究基于63例患者队列中3例高风险患者的前列腺肿瘤细胞分布图,为均匀与非均匀DIL推量生成7种治疗模式的计划并比较。共42个计划均未违反剂量约束;超过50%的非均匀推量计划较均匀推量计划提高TCP,IMPT可能最大化无毒有效治疗的可能性。
要点
- 非均匀DIL推量在多数计划中较均匀推量提高肿瘤控制概率。
- 42个计划均未违反剂量约束,涵盖7种治疗模式。
- IMPT结合非均匀DIL推量可能最大化有效且无毒治疗的可能性。
核心结论
- 基于结构处方的非均匀DIL推量可使多数均匀DIL推量计划获得更高的TCP改善。
研究设计与样本
- 从63例患者队列中选取3例具有不同DIL体积的高风险患者,基于其肿瘤细胞分布图生成均匀与非均匀DIL推量计划。
- 为所有患者生成7种治疗模式的治疗计划,共42个计划,其中均匀与非均匀DIL推量计划各21个。
主要发现
- 42个计划均未违反任何剂量约束。
- 超过50%的非均匀DIL推量计划相对均匀DIL推量计划实现了TCP提高。
- 与均匀DIL推量相比,IMPT实施非均匀DIL推量有潜力最大化有效无毒治疗的可能性。
关键数值与推荐
- 非均匀推量处方为基于结构、旨在最大化TCP的处方。
- 计划评估以是否违反剂量约束及TCP变化为比较指标。
临床怎么用
- 在前列腺放疗中可考虑基于肿瘤细胞空间分布的非均匀DIL推量以提升TCP。
- IMPT可能适合用于实施非均匀DIL推量以兼顾疗效与毒性。
局限性
- 仅基于3例高风险患者的肿瘤细胞分布图进行计划比较。
- 原文未报告临床结局、毒性数据及统计检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delivering a homogeneous dominant intra-prostatic lesion (DIL) boost enables improved tumour control in prostate radiotherapy. Opportunities for further escalation of tumour control probability (TCP) may be presented by heterogeneously boosting the DIL according to the known spatially-varying characteristics of the disease. PURPOSE: To investigate the practical limits and robustness of treatment planning for both homogeneous and heterogeneous DIL boost. MATERIALS AND METHODS: The tumour cell distribution maps, representing voxel-wise distributions of estimated prostate tumour cell numbers, of three high-risk patients with various DIL volumes in a cohort of 63 patients were selected. Heterogeneous, structure-based prescriptions, which maximize TCP, were derived for DIL boosts for each patient. Treatment plans were generated for all patients for seven treatment modalities. The resulting homogeneous DIL boost plans and heterogeneous DIL boost plans were evaluated and compared. RESULTS: In total, 42 plans were generated, including 21 plans produced for a homogeneous DIL boost and for a heterogeneous DIL boost, respectively, without violating any dose constraints. For more than 50% of heterogeneous DIL boost plans, a TCP increase could be achieved relative to plans produced for a homogeneous DIL boost. Compared to a homogeneous DIL boost, intensity modulated proton therapy (IMPT) has the potential to maximize the likelihood of effective toxicity-free treatment by implementing heterogeneous DIL boost. CONCLUSION: Heterogeneous DIL boost implemented by structure-based prescriptions enabled higher TCP improvements for the majority of plans produced for a homogeneous DIL boost.
引用
- Zhao Y, Haworth A, Williams S, et al. Homogeneous and heterogeneous boosting in prostate radiotherapy: Treatment planning and target dosimetry comparison. Radiother Oncol. 2025. PMID: 40320175. doi:10.1016/j.radonc.2025.110916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。